Patents Examined by Evelyn Mei Huang
  • Patent number: 7078523
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: July 18, 2006
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Patent number: 7074806
    Abstract: A compound of Formula (IA) or Formula (IB) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, or a tautomer prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: July 11, 2006
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Thomas Martin Kirrane, Jr., Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, David Thomson
  • Patent number: 7049439
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: May 23, 2006
    Assignee: 3M Innovative Properties Co.
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Patent number: 7041675
    Abstract: The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: May 9, 2006
    Assignee: Abbott GmbH & Co. KG
    Inventors: Wilfried Lubisch, Michael Kock, Thomas Hoeger, Roland Grandel, Reinhold Mueller, Sabine Schult
  • Patent number: 7037919
    Abstract: Tetrahydroquinoline derivatives of general formula (I) or salts thereof, having a specific and strong binding affinity for AR and exhibiting AR agonism or antagonism; and pharmaceutical compositions containing the derivatives or the salts.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: May 2, 2006
    Assignee: Kaken Pharmaceutical Co. Ltd.
    Inventors: Keigo Hanada, Kazuyuki Furuya, Kiyoshi Inoguchi, Motonori Miyakawa, Naoya Nagata
  • Patent number: 7030128
    Abstract: A class of imidazo[1,2-?]pyrimidine derivatives, substituted at the 3-position by an optionally substituted five-membered or six-membered heteroaromatic ring, are selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: April 18, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Wesley Peter Blackaby, Jose Luis Castro Pineiro, Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Philip Jones, Richard Thomas Lewis, Angus Murray MacLeod, Robert James Maxey, Kevin William Moore, Leslie Joseph Street
  • Patent number: 7012080
    Abstract: This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a methyl group or an ethyl group; R3 represents a branched alkyl group having from 3 to 6 carbon atoms or an alkyl group having from 3 to 6 carbon atoms substituted by an alkoxy group having from 1 to 6 carbon atoms; with the proviso that when the terminal carbon atom of said alkyl group of R3 is substituted by said alkoxy group, said alkyl group is a branched alkyl group. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: March 14, 2006
    Assignee: Pfizer Inc.
    Inventors: Satoru Iguchi, Yasuhiro Katsu, Kana Kon-I, Hirohide Noguchi, Chikara Uchida
  • Patent number: 7001900
    Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1–2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1–2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which ?7 is known to be involved.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: February 21, 2006
    Assignee: Pfizer Inc.
    Inventors: Eric Jon Jacobsen, Jason K. Myers, Daniel Patrick Walker, Donn G. Wishka, Steven Charles Reitz, David W. Piotrowski, Brad A. Acker, Vincent E. Groppi, Jr.
  • Patent number: 6992086
    Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: January 31, 2006
    Assignee: Telik, Inc.
    Inventors: Edgardo Laborde, Louise Robinson, Fanying Meng, Brian T. Peterson, Hugo O. Villar, Steven E. Anuskiewicz, Yoshiro Ishiwata, Shoji Yokochi, Yukiharu Matsumoto, Takuji Kakigami, Hideaki Inagaki, Takahito Jomori, Kouji Matsushima
  • Patent number: 6992095
    Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: January 31, 2006
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Jean-Michel Bernardon, Bruno Charpentier
  • Patent number: 6989390
    Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X? or R1 is —(CH2)nN+HR3R4 X? or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X?? sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X? is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: January 24, 2006
    Assignee: Xanthus Life Sciences, Inc.
    Inventors: Alfred M. Ajami, David O. Barlow
  • Patent number: 6989389
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: January 24, 2006
    Assignee: 3M Innovative Properties Co.
    Inventors: Philip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
  • Patent number: 6987115
    Abstract: Compounds of the formula (I) are disclosed and are useful in the treatment bacterial infections: wherein: R1 is Ar or Het; R2 is C1-6alkyl, (R?)2N—(CH2)m— or Ar—C0-6alkyl; X is H, C1-4alkyl, OR?, SR?, C1-4alkylsulfonyl, C1-4alkylsulfoxyl, CN, N(R?)2, CH2N(R?)2, NO2, CF3, CO2R?, CON(R?)2, COR?, NR?C(O)R?, F, Cl, Br, I, or CF3S(O)r—; R? is H, C1-6alkyl or Ar—C0-6alkyl; each R? independently is H, C1-6alkyl or Ar—C0-6alkyl; m is 1 or 2; n is 0, 1 or 2; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: January 17, 2006
    Assignee: SmithKline Beecham Corporation
    Inventor: Mark A. Seefeld
  • Patent number: 6987117
    Abstract: Compounds of the formula useful for the treatment of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse, and dysthymia.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: January 17, 2006
    Assignee: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Patent number: 6987116
    Abstract: This invention provides compounds of Formula (1a)-(1f) wherein: X, R1, and R2 are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: January 17, 2006
    Assignee: Wyeth
    Inventors: Diane Harris Boschelli, Nan Zhang, Ana Carolina Barrios Sosa, Haris Durutlic, Biqi Wu
  • Patent number: 6984635
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: January 10, 2006
    Assignees: Board of Trustees of The Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Stuart L. Schreiber, Gerald R. Crabtree, Stephen D. Liberles
  • Patent number: 6984646
    Abstract: The invention relates to imidazopyridinones of the formula wherein the groups R1, R2, R3, and R4 are as defined in claim 1, to the process for their preparation, to pharmaceutical compositions containing them, and to a method of using them for treatment of chronic inflammatory processes in humans or animals.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: January 10, 2006
    Assignee: Bayer Healhcare AG
    Inventors: Cristina Alonso-Alija, Martin Michels, Hartmut Schirok, Karl-Heinz Schlemmer, Sara Dodd, Mary Fitzgerald, John Bell, Andrew Gill
  • Patent number: 6982271
    Abstract: The present invention provides compounds, specifically novel tropane analogs, capable of acting as inhibitors of reuptake of monoamines. In preferred embodiments, these compositions are selective inhibitors of serotonin and/or norepinephrine reuptake. Also provided herein are pharmaceutical compositions comprising novel tropane analogs and a pharmaceutically acceptable carrier, and methods for treating conditions in which inhibition of reuptake of monoamines is desired. The inventive compositions as described herein are also useful for medical therapy and diagnosis.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: January 3, 2006
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Wolfgang Alexander Hoepping
  • Patent number: 6982334
    Abstract: The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure: and as characterized herein by powder X-ray diffraction patterns as form A and form B, processes for preparing form A from the purified amorphous form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a processes for preparing form A by heating monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a pharmaceutical composition comprising form A, a pharmaceutical composition comprising form A and form B or monohydrated form C, a pharmaceutical composition comprising form A, form B and monohydrated form C, a method for treating a bacterial infection with form A, a method for treating a bacterial infection with form A and form B or monohydrated form C, and a method f
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: January 3, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Jacques Bourget, Marc Antoine Perrin, Serge Mignani, Bernd Janocha, Michel Cheve, Carole Neves, Pascal Billot, Michel Tabart, Sylvaine Lafont
  • Patent number: RE39128
    Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: June 13, 2006
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Valerie Joan Berry, Steven Dabbs, Colin Henry Frydrych, Eric Hunt, Francis Dominic Sanderson, Gary Woodnutt